Non-inferiority trials: why oncologists must remain wary

Mauricio Burotto, Vinay Prasad, Tito Fojo

Research output: Contribution to journalArticle

9 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)364-366
Number of pages3
JournalThe Lancet Oncology
Volume16
Issue number4
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Drug Approval
Antineoplastic Agents
Neoplasms
Oncologists

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Non-inferiority trials : why oncologists must remain wary. / Burotto, Mauricio; Prasad, Vinay; Fojo, Tito.

In: The Lancet Oncology, Vol. 16, No. 4, 2015, p. 364-366.

Research output: Contribution to journalArticle

Burotto, Mauricio ; Prasad, Vinay ; Fojo, Tito. / Non-inferiority trials : why oncologists must remain wary. In: The Lancet Oncology. 2015 ; Vol. 16, No. 4. pp. 364-366.
@article{a966d5252636431eb85937f6c24a4fbe,
title = "Non-inferiority trials: why oncologists must remain wary",
author = "Mauricio Burotto and Vinay Prasad and Tito Fojo",
year = "2015",
doi = "10.1016/S1470-2045(15)70129-4",
language = "English (US)",
volume = "16",
pages = "364--366",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "4",

}

TY - JOUR

T1 - Non-inferiority trials

T2 - why oncologists must remain wary

AU - Burotto, Mauricio

AU - Prasad, Vinay

AU - Fojo, Tito

PY - 2015

Y1 - 2015

UR - http://www.scopus.com/inward/record.url?scp=84933523935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933523935&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)70129-4

DO - 10.1016/S1470-2045(15)70129-4

M3 - Article

C2 - 25846084

AN - SCOPUS:84933523935

VL - 16

SP - 364

EP - 366

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -